RxDoctor Payments Data

Kathy Brinkman, NP

Family · Monroe City, INNPI 1750326906

Payments from drug & device makers

$9,161in general payments, 2019–2025

Across 598 payments — averaging $15.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Merck$556
  • Lilly USA, LLC$540
  • Amgen$524
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$9,161100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,161 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$100,654
Medicare patients
369
Services billed
2,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban26$25,260
OzempicSemaglutide19$18,924
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,424
Xigduo XrDapaglifloz Propaned/Metformin16$12,293
Synjardy XrEmpagliflozin/Metformin Hcl13$12,104
FarxigaDapagliflozin Propanediol14$10,190
Rosuvastatin Calcium137$1,689
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen95$1,434
Albuterol Sulfate HfaAlbuterol Sulfate46$1,381
Atorvastatin Calcium148$1,213
Pantoprazole Sodium62$916
Carbidopa-LevodopaCarbidopa/Levodopa12$769
Potassium Chloride19$762
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen30$695
Alprazolam95$671

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$459$25,26026 claims
Novo NordiskOzempic$1,075$18,92419 claims
GSKTrelegy Ellipta$363$17,42426 claims
Boehringer IngelheimSynjardy Xr$146$12,10413 claims
AstraZenecaFarxiga$1,031$10,19014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Monroe City

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →